ESR1 and metastatic prostate carcinoma: Notably, the most significantly enriched variants in the metastasis include ESR1 (estrogen receptor 1) mutation in metastatic breast cancer (FDR < 1e−6, z-test, Benjamini–Hochberg (BH) correction) and AR (androgen receptor) mutation and copy-number amplification in metastatic prostate cancer (FDR < 1e−6, z-test, BH correction).